• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Cardiology

Weight fluctuations associated with mortality in patients with coronary artery disease

byAndrew Cheung, MD MBAandJames Roebker
April 7, 2017
in Cardiology, Chronic Disease, Endocrinology, Public Health
Reading Time: 3 mins read
Long-term outcomes for off-pump and on-pump CABG are similar
Share on FacebookShare on Twitter

1. In patients with coronary artery disease (CAD), increased body-weight variability demonstrated a graded increased risk of cardiovascular events and death.

2. The association of increased cardiovascular events and mortality was higher in obese or overweight patients compared to those with normal weight.

Evidence Rating Level: 2 (Good)       

Study Rundown: Many patients prescribed weight reduction for the management of cardiovascular disease find it difficult to maintain the lower weight and experience cycles of weight loss and gain. The prognostic significance of these fluctuations is unknown and an area of controversy. This study explored the association of weight fluctuation with the risk of cardiovascular events in a large cohort of patients with known CAD. The primary outcome – any coronary event – demonstrated a graded increase with weight variability, with the strongest association in those with baseline obesity. Secondary outcomes – including any cardiovascular event, death, myocardial infarction (MI), and stroke – all were significantly higher with increased weight variability. New-onset diabetes was evaluated as an additional outcome and was significantly higher with increased weight variability. This data suggests that weight variability is an independent prognostic indicator in those with coronary artery disease.

The authors conducted a post hoc analysis using data of patients with CAD in the randomized Treating to New Targets (TNT) trial. This trial had a large cohort that excluded patients with a poor prognosis and included a sensitivity analysis (excluding patients with a history of heart failure) to reduce possible confounders. Limitations include the retrospective study design (precludes testing for causation), the use of BMI to measure obesity (insensitive to body composition), and the smaller sample size of the sensitivity analyses (underpowered for outcome assessment beyond a certain cutoff point).

Click to read the study in NEJM

RELATED REPORTS

150 minutes of moderate-to-vigorous physical activity per week may reduce cardiovascular risk in overweight or obese adults

Amycretin significantly improves weight loss in patients with overweight or obese body weight

New obesity framework may reclassify over half of overweight individuals as people with obesity

Relevant Reading: Intensive lipid lowering with atorvastatin in patients with stable coronary disease

In-Depth [retrospective cohort study]: This post hoc analysis collected data on 9509 patients from the TNT trial with at least two post-baseline measurements of body weight. Patients were followed at 3, 6, 9, and 12 months and every 6 months thereafter. The main variability measure was absolute differences in successive weight. The primary outcome was any coronary event (a composite of coronary artery disease, nonfatal MI, resuscitated cardiac arrest, revascularization, or angina) evaluated as a time-dependent covariate. Secondary outcomes included any cardiovascular event, death, MI, and stroke, evaluated as a non-time-dependent covariate. New-onset diabetes was included as an additional outcome.

The median duration between first and last weight measurements was 4.7 years (median number of measurements, 12). Using body-weight as a time-dependent covariate, each 1 standard deviation (SD) increase in variability increased the risk of any coronary event (hazard ratio [HR], 1.04; 95% confidence interval [CI], 1.01 to 1.07; p = 0.01), any cardiovascular event (HR, 1.04; 95% CI, 1.02 to 1.07; p < 0.01), and death (HR, 1.09; 95% CI, 1.07 to 1.12; p < 0.001). In the non-time-dependent covariate analysis, each 1 SD increase in variability increased the risk of any coronary event (HR, 1.04; 95% CI, 1.02 to 1.06; p < 0.001), cardiovascular event (HR, 1.04; 95% CI, 1.03 to 1.06; p < 0.001), death (HR, 1.03; 95% CI, 1.01 to 1.06; p = 0.01), MI (HR, 1.04; 95% CI, 1.00 to 1.07; p = 0.04), and stroke (HR, 1.05; 95% CI, 1.00 to 1.09; p = 0.03). Body-weight variability was also associated with an increase in new-onset diabetes (HR, 1.08; 95% CI, 1.02 to 1.14; p = 0.009). The strongest associations were found in those with the highest baseline BMI, and high body-weight variability was no significant in those with a normal BMI. Sensitivity analyses that excluded patients with only two measures of body-weight, a history of heart failure, or used other measures of variability yielded similar results.

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Coronary artery diseaseoverweight
Previous Post

No link between antenatal betamethasone and abnormal childhood bone development

Next Post

Long term phototherapy can enhance treatment response in vitiligo

RelatedReports

Many new pediatric asthma cases attributable to obesity
Cardiology

150 minutes of moderate-to-vigorous physical activity per week may reduce cardiovascular risk in overweight or obese adults

February 26, 2026
Many new pediatric asthma cases attributable to obesity
Cardiology

Amycretin significantly improves weight loss in patients with overweight or obese body weight

August 6, 2025
Colonic byproduct may decrease long-term weight gain
Public Health

New obesity framework may reclassify over half of overweight individuals as people with obesity

July 14, 2025
Sleep duration inversely related to childhood type 2 diabetes risk makers
Cardiology

Tirzepatide-associated improvements in cardiometabolic risk factors linked to degree of weight loss

June 23, 2025
Next Post
Long term phototherapy can enhance treatment response in vitiligo

Long term phototherapy can enhance treatment response in vitiligo

Cerebral protection device effective in patients undergoing transcatheter aortic valve implantation

Transcatheter aortic valve replacement noninferior to surgery for intermediate-risk patients: The SURTAVI trial

Epidural corticosteroid injections provide only short-term radiculopathy pain relief

Interactive voice response system effective for CBT-based therapy for chronic back pain

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • The rate of urethrocutaneous fistula formation may be similar between caudal and penile blocks
  • 2 Minute Medicine Rewind October 12, 2026
  • Gepotidacin (Blujepa) is safe and effective in women with uncomplicated urinary tract infections
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.